Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
ARCA biopharma Inc is a clinical development stage biopharmaceutical company. It applies precision medicine approach to develop genetically targeted therapies for cardiovascular diseases. The company's lead product candidates are rNAPc2 (AB201) as a potential treatment for diseases caused by ribonucleic acid, viruses, initially focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus, and Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation, in patients with chronic heart failure.
Westminster, CO, 80021